Nantkwest, Inc. News Releases https://ir.nantkwest.com/ Nantkwest, Inc. News Releases en NantKwest Launches First-in-class, First-in-human Phase I Clinical Trial With a Targeted PD-L1 t-haNK Cell Therapy in Patients With Solid Tumors https://ir.nantkwest.com/news-releases/news-release-details/nantkwest-launches-first-class-first-human-phase-i-clinical First engineered, GMP-grade, cryopreserved, off-the-shelf, bi-specific NK cell therapy to enter human clinical trials targeting PD-L1 and CD16 in patients with solid tumors NantKwest establishes a leading portfolio of off-the-shelf NK cells at clinical stage of development with three engineered Mon, 24 Jun 2019 08:00:00 -0400 Nantkwest, Inc. News Releases 7771 Cheryl Cohen Appointed to NantKwest’s Board of Directors https://ir.nantkwest.com/news-releases/news-release-details/cheryl-cohen-appointed-nantkwests-board-directors CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 6, 2019-- NantKwest ( Nasdaq:NK ) today announced the appointment of Cheryl L. Cohen to the Board of Directors of NantKwest , effective immediately. “Cheryl is a proven business executive and highly experienced board member in both the biotechnology and Thu, 06 Jun 2019 16:10:00 -0400 Nantkwest, Inc. News Releases 7726 NantKwest Announces Durable Complete Responses in Multiple Advanced-Stage Solid Tumor Cancers Following Off-the-Shelf NK Cell Therapy in First 35 Patients https://ir.nantkwest.com/news-releases/news-release-details/nantkwest-announces-durable-complete-responses-multiple-advanced 5 out of 35 Durable Complete Responses Observed in Patients with Relapsed Third-Line Advanced Solid Tumors with Duration Ranging 4 to 24 Months CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 4, 2019-- Patrick Soon-Shiong , MD, Chairman and CEO of NantKwest (Nasdaq:NK), a leading clinical-stage, Tue, 04 Jun 2019 08:00:00 -0400 Nantkwest, Inc. News Releases 7706 NantKwest Announces Updated Clinical Results for Nanatinostat (VRx-3996), a Novel HDAC Inhibitor Being Developed in Partnership with Viracta Therapeutics https://ir.nantkwest.com/news-releases/news-release-details/nantkwest-announces-updated-clinical-results-nanatinostat-vrx Phase Ib/II Clinical Trial Data Reported at 2019 Annual Meeting of the American Society of Clinical Oncology Shows High Overall Objective Response Rate (ORR) of 58% and Complete Response Rate (CR) of 33% in Relapsed/Refractory Lymphoma Patients CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. Tue, 04 Jun 2019 07:45:00 -0400 Nantkwest, Inc. News Releases 7701 NantKwest Launches First-in-Human Targeted NK Phase I Clinical Trial of CD19 T-haNK Cell Therapy in Lymphoma Patients https://ir.nantkwest.com/news-releases/news-release-details/nantkwest-launches-first-human-targeted-nk-phase-i-clinical First engineered, GMP-grade, cryopreserved, off-the-shelf, bi-specific NK cell therapy to enter human clinical trials targeting CD16 and CD19 in patients with lymphoma CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 3, 2019-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage Mon, 03 Jun 2019 14:50:00 -0400 Nantkwest, Inc. News Releases 7696 NantKwest to Present and Provide Update at Upcoming Jefferies 2019 Annual Healthcare Conference https://ir.nantkwest.com/news-releases/news-release-details/nantkwest-present-and-provide-update-upcoming-jefferies-2019 CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 3, 2019-- NantKwest ( Nasdaq:NK ), a leading clinical-stage, natural killer cell based therapeutics company, today announced that Dr. Patrick Soon-Shiong and Company management will be participating in the Jefferies 2019 Annual Healthcare Conference being Mon, 03 Jun 2019 08:00:00 -0400 Nantkwest, Inc. News Releases 7691 NantKwest, NantCell and NantOmics to Provide Updated Preclinical and Clinical Data in Four Abstracts at Part of the American Society of Clinical Oncology Annual Meeting https://ir.nantkwest.com/news-releases/news-release-details/nantkwest-nantcell-and-nantomics-provide-updated-preclinical-and Preclinical and Clinical Data Demonstrate Advanced Deployment of Precision Medicine Tools to Analyze and Potentially More Effectively Intervene with Highly Focused Therapeutic Interventions CULVER CITY, Calif. --(BUSINESS WIRE)--May 31, 2019-- NantKwest ( Nasdaq:NK ), a leading clinical-stage, Fri, 31 May 2019 08:00:00 -0400 Nantkwest, Inc. News Releases 7686 Brink Biologics Announces Research License Agreement with Worcester Polytechnic Institute for Use of NantKwest’s NK-92® Cells https://ir.nantkwest.com/news-releases/news-release-details/brink-biologics-announces-research-license-agreement-worcester NK-92® Cell Based Bioanalytical Solutions are the Key to Optimizing R&D and Commercial Product Development Efforts for Monoclonal Antibodies, Bi-Specifics and Related Biological Products SAN DIEGO --(BUSINESS WIRE)--May 1, 2019-- Brink Biologics, Inc. , a  NantKwest, Inc. Wed, 01 May 2019 08:00:00 -0400 Nantkwest, Inc. News Releases 7656 NantKwest Announces New haNK Natural Killer Cell Patent Issuance Further Expanding Intellectual Property Estate https://ir.nantkwest.com/news-releases/news-release-details/nantkwest-announces-new-hank-natural-killer-cell-patent-issuance New haNK and T-haNK Based Natural Killer Cell Therapy Programs to Transition to Human Clinical Trials in 2019 CULVER CITY, Calif. --(BUSINESS WIRE)--Apr. 1, 2019-- NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the Company has Mon, 01 Apr 2019 08:00:00 -0400 Nantkwest, Inc. News Releases 7641 NantKwest Chairman & CEO Dr. Patrick Soon-Shiong Exercises $39 Million in Warrants and Options in Support of NK’s Natural Killer Cell Strategic Vision Beyond Check Point Immunotherapy https://ir.nantkwest.com/news-releases/news-release-details/nantkwest-chairman-ceo-dr-patrick-soon-shiong-exercises-39 Completion of Phase 1 First-in-Human Trials of Cryopreserved, Off-The-Shelf haNK Cells Leads the Way to Pivotal Phase 2 Trials in Relapsed Merkel Cell Carcinoma Funding to Support INDs for First-in-Human Targeted Off-The-Shelf NK Cells (t-haNKs) with PD-L1 and CD-19 as Tumor Targets CULVER CITY, Mon, 25 Mar 2019 08:00:00 -0400 Nantkwest, Inc. News Releases 7616